semustine has been researched along with Cancer of Esophagus in 2 studies
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 5.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 1.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, G | 1 |
| Chen, L | 1 |
| Wu, S | 1 |
| Feng, Y | 1 |
| Lin, T | 1 |
| Karlin, DA | 1 |
| Stroehlein, JR | 1 |
| Bennetts, RW | 1 |
| Jones, RD | 1 |
| Heifetz, LJ | 1 |
| Mahal, PS | 1 |
2 other studies available for semustine and Cancer of Esophagus
| Article | Year |
|---|---|
Comprehensive Analysis of Tumor-Infiltrating Immune Cells and Relevant Therapeutic Strategy in Esophageal Cancer.
Topics: Adult; Algorithms; Antineoplastic Agents; Cell Count; Databases, Factual; Dendritic Cells; Esophagea | 2020 |
Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1982 |